Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group
Public DepositedAdd to collection
You do not have access to any existing collections. You may create a new collection.
Downloadable Content
Download PDFCitation
MLA
Peyser, Alexandra, et al. Follow-up of Phase I Trial of Adalimumab and Rosiglitazone In Fsgs: Iii. Report of the Font Study Group. BioMed Central Ltd, 2010. https://doi.org/10.17615/jst0-fm48APA
Peyser, A., Mac Hardy, N., Tarapore, F., Mac Hardy, J., Powell, L., Gipson, D., Savin, V., Pan, C., Kump, T., Vento, S., & Trachtman, H. (2010). Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BioMed Central Ltd. https://doi.org/10.17615/jst0-fm48Chicago
Peyser, Alexandra, Nathaniel Mac Hardy, Freya Tarapore, Jacqueline Mac Hardy, Leslie M Powell, Debbie S Gipson, Virginia Savin et al. 2010. Follow-Up of Phase I Trial of Adalimumab and Rosiglitazone In Fsgs: Iii. Report of the Font Study Group. BioMed Central Ltd. https://doi.org/10.17615/jst0-fm48- Creator
-
Peyser, Alexandra
- Other Affiliation: Department of Pediatrics, Division of Nephrology, Schneider Children’s Hospital of North Shore-LIJ Health System, 269-01 76th Avenue, New Hyde Park, NY 11040, USA
-
MacHardy, Nathaniel
- Affiliation: School of Medicine, Department of Medicine, Division of Nephrology and Hypertension
-
Tarapore, Freya
- Other Affiliation: Department of Pediatrics, Division of Nephrology, Schneider Children’s Hospital of North Shore-LIJ Health System, 269-01 76th Avenue, New Hyde Park, NY 11040, USA
-
MacHardy, Jacqueline
- Affiliation: School of Medicine, Department of Medicine, Division of Nephrology and Hypertension
-
Powell, Leslie M
- Affiliation: School of Medicine, Department of Medicine, Division of Nephrology and Hypertension
-
Gipson, Debbie S
- Affiliation: School of Medicine, Department of Medicine, Division of Nephrology and Hypertension
-
Savin, Virginia
- Other Affiliation: Department of Medicine, Division of Nephrology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226, USA
-
Pan, Cynthia
- Other Affiliation: Department of Pediatrics, Division of Nephrology, Children’s Hospital of Wisconsin, 999 North 92nd Street, Wauwatosa, WI 53227, USA
-
Kump, Theresa
- Other Affiliation: Department of Pediatrics, Division of Nephrology, Children’s Hospital of Wisconsin, 999 North 92nd Street, Wauwatosa, WI 53227, USA
-
Vento, Suzanne
- Other Affiliation: Department of Pediatrics, Division of Nephrology, Schneider Children’s Hospital of North Shore-LIJ Health System, 269-01 76th Avenue, New Hyde Park, NY 11040, USA
-
Trachtman, Howard
- Other Affiliation: Department of Pediatrics, Division of Nephrology, Schneider Children’s Hospital of North Shore-LIJ Health System, 269-01 76th Avenue, New Hyde Park, NY 11040, USA
- Abstract
- Abstract Background Patients with resistant primary focal segmental glomerulosclerosis (FSGS) are at high risk of progression to chronic kidney disease stage V. Antifibrotic agents may slow or halt this process. We present outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibrotic drugs tested in the Novel Therapies in Resistant FSGS (FONT) study. Methods 21 patients -- 12 males and 9 females, age 16.0 ± 7.5 yr, and estimated GFR (GFRe) 121 ± 56 mL/min/1.73 m2 -- received adalimumab (n = 10), 24 mg/m2 every 14 days or rosiglitazone (n = 11), 3 mg/m2 per day for 16 weeks. The change in GFRe per month prior to entry and after completion of the Phase I trial was compared. Results 19 patients completed the 16-week FONT treatment phase. The observation period pre-FONT was 18.3 ± 10.2 months and 16.1 ± 5.7 months after the study. A similar percentage of patients, 71% and 56%, in the rosiglitazone and adalimumab cohorts, respectively, had stabilization in GFRe, defined as a reduced negative slope of the line plotting GFRe versus time without requiring renal replacement therapy after completion of the FONT treatment period (P = 0.63). Conclusion Nearly 50% of patients with resistant FSGS who receive novel antifibrotic agents may have a legacy effect with delayed deterioration in kidney function after completion of therapy. Based on this proof-of-concept preliminary study, we recommend long-term follow-up of patients enrolled in clinical trials to ascertain a more comprehensive assessment of the efficacy of experimental treatments.
- Date of publication
- January 29, 2010
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- Rights holder
- Alexandra Peyser et al.; licensee BioMed Central Ltd.
- License
- Journal title
- BMC Nephrology
- Journal volume
- 11
- Journal issue
- 1
- Page start
- 2
- Language
- English
- Is the article or chapter peer-reviewed?
- Yes
- ISSN
- 1471-2369
- Bibliographic citation
- BMC Nephrology. 2010 Jan 29;11(1):2
- Publisher
- BioMed Central Ltd
- Access right
- Open Access
- Date uploaded
- July 15, 2016
Relations
- Parents:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
12882_2009_article_153.pdf | 2019-05-06 | Public | Download | |
12882_2009_153_moesm1_esm.pdf | 2019-05-06 | Public | Download | |
12882_2009_153_moesm2_esm.pdf | 2019-05-06 | Public | Download |